Shire Full Of Hopes For Vyvanse Binge-Eating Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
First Phase II results in expansion program for the ADHD therapy show strong response in the eating disorder, but the company faces a regulatory challenge in gaining the first approval for the condition.
You may also be interested in...
Phase III Results Give Shire’s Vyvanse A Boost In Binge Eating
Blockbuster ADHD drug Vyvanse shows efficacy for reducing the frequency of binge eating in two Phase III trials, opening the door to a new indication. Shire plans to file an sNDA by the third quarter of 2014.
Phase III Results Give Shire’s Vyvanse A Boost In Binge Eating
Blockbuster ADHD drug Vyvanse shows efficacy for reducing the frequency of binge eating in two Phase III trials, opening the door to a new indication. Shire plans to file an sNDA by the third quarter of 2014.
Shire Wrings Life Out Of Adderall XR Despite Actavis Generic Launch
Branded Adderall XR will remain competitive, Shire CEO Angus Russell predicts during the company’s second quarter sales and earnings call, despite the launch of the first generic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: